Challenge I Winners
16 Round One Awardees for Head Health Challenge I were announced on January 23, 2014.
GE and the NFL have announced six final winners in Challenge I. Each Winner will receive a $500,000 award to advance their work to speed diagnosis and improve treatment for mild traumatic brain injury. This award is in addition to $300,000 previously awarded to the 16 first round winners of Head Health Challenge I. Download the Press Release >>
Challenge I Final Six Award Winners and their areas of research and innovation:
Banyan Biomarkers, Inc. San Diego, Calif. - Banyan Biomarkers, Inc. is developing a point-of-care blood test to rapidly detect the presence of mild and moderate brain trauma to improve the medical management of head injured patients. Researchers from Banyan Biomarkers and the University of Florida are collaborating on a sports concussion study to analyze biomarkers, neurocognitive testing, and neuroimaging on student athletes. Banyan expects twenty blood-based markers for head injury will be added to the study in the coming year which will help provide researchers a better understanding of the biochemical pathways that occur in the brain after a concussion and, ultimately, assist to develop treatments to improve clinical outcomes.
BrainScope Company, Inc. Bethesda, Md. - BrainScope, in collaboration with the Purdue Neurotrauma Group, conducted a study of athletes using both neuroimaging tools as well as BrainScope’s urgent care, handheld, EEG-based traumatic brain injury detection technology. The research supported the utility of the BrainScope markers as a surrogate for neuroimaging and revealed its potential to identify those with increased vulnerability and susceptibility to concussion. BrainScope is developing a concussion assessment system to identify concussed from non-concussed patients and provide a method for assessment of concussed patients over time. This system in development is intended for use by clinicians from initial point-of-care assessment to rehabilitation of head-injured patients.
Medical College of Wisconsin, Milwaukee, Wis.
- Using MRI scanning technology, researchers at the Medical College of Wisconsin are determining the direct effects of sports-related concussions on brain structure and function. The aim of the study is to advance the discovery of more objective biomarkers to assist in diagnosing concussion, determining when an athlete’s brain has fully recovered, and clinical decision making about the athlete’s fitness to return to play after a concussion.
Quanterix, Lexington, Mass. - Quanterix has developed a simple blood test to aid in the detection of traumatic brain injury. Using its Simoa technology, Quanterix is able to measure molecular signatures (biomarkers) of brain injury in blood. Quanterix is working to detect and quantify mild to moderate traumatic brain injury almost immediately after the injury has taken place, which will help to better predict the long-term prognosis of individuals who have undergone acute and repetitive injuries. Quanterix’s goal is to provide a blood test that speeds the diagnosis of a concussion in a clinical setting and on the sidelines in a sports arena, therefore improving and accelerating treatment.
University of California, Santa Barbara (UCSB), Santa Barbara, Calif. - The UCSB Brain Imaging Center, in collaboration with faculty in the computer sciences, is developing statistical methods to detect damage to the deep connections in the brains of patients after mild head injury. Recent breakthroughs in both MRI scanning and data analysis make it possible to detect subtle brain changes in individual patients after mild concussions. This approach will be tested with clinical data from collaborators using a variety of MRI scanners.
University of Montana, Missoula, Mont. - Researchers at the University of Montana have identified blood-based biomarkers that indicate how the brain reacts following a traumatic brain injury (TBI). Research over the past year has demonstrated changes in specific plasma microRNAs (micro ribonucleic acids) in TBI patients over a period of several months. The identification and validation of these markers could help with diagnosis and assessing recovery after a head injury as well as testing the effectiveness of new treatments for TBI.